argenx SE (NASDAQ:ARGX) Shares Acquired by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. lifted its stake in argenx SE (NASDAQ:ARGX) by 78.6% in the 4th quarter, Holdings Channel reports. The firm owned 75 shares of the company’s stock after purchasing an additional 33 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in argenx were worth $46,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. iA Global Asset Management Inc. increased its holdings in argenx by 5.0% in the fourth quarter. iA Global Asset Management Inc. now owns 5,640 shares of the company’s stock valued at $3,469,000 after buying an additional 270 shares in the last quarter. Maryland State Retirement & Pension System grew its holdings in shares of argenx by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 3,510 shares of the company’s stock worth $2,159,000 after acquiring an additional 38 shares during the period. Signaturefd LLC grew its holdings in shares of argenx by 10.2% in the 4th quarter. Signaturefd LLC now owns 1,804 shares of the company’s stock worth $1,109,000 after acquiring an additional 167 shares during the period. Parallel Advisors LLC increased its stake in argenx by 12.7% in the 4th quarter. Parallel Advisors LLC now owns 676 shares of the company’s stock valued at $416,000 after purchasing an additional 76 shares in the last quarter. Finally, Corient Private Wealth LLC raised its holdings in argenx by 14.7% during the fourth quarter. Corient Private Wealth LLC now owns 1,485 shares of the company’s stock worth $913,000 after purchasing an additional 190 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on ARGX shares. Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a report on Tuesday, January 7th. Oppenheimer increased their price objective on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “sell” rating to a “hold” rating in a report on Wednesday, March 12th. Citigroup reaffirmed an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, Guggenheim raised their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Trading Down 1.1 %

Shares of NASDAQ:ARGX opened at $607.95 on Tuesday. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The stock’s 50-day moving average price is $633.44 and its two-hundred day moving average price is $600.67. The firm has a market cap of $36.94 billion, a price-to-earnings ratio of -690.85 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $761.22 million for the quarter, compared to analysts’ expectations of $678.52 million. As a group, research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.